BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15534130)

  • 1. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
    Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
    Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
    Albert DM; Gangnon RE; Grossniklaus HE; Green WR; Darjatmoko S; Kulkarni AD
    Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphometric effects of long-term exposure to latanoprost.
    Cracknell KP; Grierson I; Hogg P
    Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
    Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
    Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of irises with a latanoprost-induced change in iris color.
    Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
    Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
    Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
    J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology and fine structure of the iris and outflow system following latanoprost therapy.
    Grierson I; Pfeiffer N; Cracknell KP; Appleton P
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
    Wistrand PJ; Stjernschantz J; Olsson K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.
    Chiba T; Kashiwagi K; Kogure S; Abe K; Shibuya T; Furuichi M; Iijima H; Tsukahara S
    J Glaucoma; 2001 Oct; 10(5):406-10. PubMed ID: 11711839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
    Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
    Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iris morphology.
    Teus MA; Arranz-Marquez E
    Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
    [No Abstract]   [Full Text] [Related]  

  • 12. Latanoprost and pigmentation.
    Grierson I; Jonsson M; Cracknell K
    Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.
    Yildirim N; Sahin A; Kara S; Baycu C
    Int Ophthalmol; 2010 Feb; 30(1):93-7. PubMed ID: 19139827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study.
    Pfeiffer N; Grierson I; Goldsmith H; Hochgesand D; Winkgen-Böhres A; Appleton P
    Arch Ophthalmol; 2001 Feb; 119(2):191-6. PubMed ID: 11176979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes.
    Latanoprost-Induced Iris Pigmentation Study Group
    Jpn J Ophthalmol; 2006; 50(2):96-9. PubMed ID: 16604382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
    Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
    Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
    Alm A; Schoenfelder J; McDermott J
    Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin-induced iridial pigmentation in primates.
    Selén G; Stjernschantz J; Resul B
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S125-8. PubMed ID: 9154288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
    Grierson I; Lee WR; Albert DM
    Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue.
    Lindquist NG; Larsson BS; Stjernschantz J
    Exp Eye Res; 1999 Oct; 69(4):431-6. PubMed ID: 10504276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.